The iCELLigence system will allow me to further interrogate cancer cell proliferation, metabolic function, cell-cell interactions, and how the tumor microenvironment is affected by molecular perturbations and influences therapeutic response in patients.
San Diego, CA (PRWEB) September 29, 2014
ACEA Biosciences, Inc. (ACEA) has awarded Jonathan Chen at Yale University the 2014 iCELLigence Research Grant for his proposal on cancer cell drug resistance studies. ACEA’s iCELLigence instrument is an impedance based real-time label-free cellular analysis instrument. Jonathan Chen, a Ph.D. candidate in Department of Biomedical Engineering at Yale University currently holds a NSF Graduate Research Fellowship. Chen’s research projects in Professor Rong Fan's laboratory involve the investigation of molecular correlates of cancer cell drug resistance using a suit of single cell analysis tools. He plans to work closely with the interface of biology and engineering to analyze the complex cellular heterogeneity in tumor microenvironments and utilize this understanding towards the direction of personalized medicine.
“I am extremely excited,” Jonathan stated upon receiving the award, “The iCELLigence system will allow me to further interrogate cancer cell proliferation, metabolic function, cell-cell interactions, and how the tumor microenvironment is affected by molecular perturbations and influences therapeutic response in patients.”
Cancer is the second leading cause of death in the United States. Chemotherapy is one of the major methods to combat cancer, but the effectiveness of chemotherapy is limited by drug resistance. Research is under way on many fronts to better understand drug resistance in cancer and to find therapeutics that may overcome or reverse the development of drug resistance.
“We are very pleased to support young cancer researcher with the necessary tools to tackle cancer drug resistance,” noted Yama Abassi, Ph.D., Vice President of ACEA Biosciences, Inc. “ACEA Biosciences will continue to work closely with scientists throughout the world to bring innovation to health care industries.”
Media Contact: Leyna Zhao, Ph.D., Global Marketing Manager| lzhao(at)aceabio(dot)com | http://www.aceabio.com
About the ACEA’s iCELLigence Research Grant
ACEA’s iCELLigence Research Grant is focused on assisting early career scientists to achieve their research goals by providing them free access to RTCA technology. This international research grant provides the scientist an iCELLigence System, consumables, and consultation for up to 6 months. The next deadline for application is December 15, 2014. For more information about the grant, please visit http://www.aceabio.com/grant or write to grant(at)aceabio(dot)com.
About ACEA Biosciences
Founded in 2002, ACEA Biosciences, Inc. (ACEA) is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. Researchers are advancing their studies utilizing 1,300+ placed instruments for broad and diverse applications. The technology has been cited in over 600 peer reviewed publications. ACEA’s xCELLigence® impedance-based, label-free, real time cell analysis system and NovoCyte™ flow cytometers are used in pre-clinical drug discovery and development, toxicity, safety pharmacology, and basic academic research.